UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.

Authors :: Petrioli, R.
Sabatino, M.
Fiaschi, A.I.
Marsili, S.
Pozzessere, D.
Messinese, S.
Correale, P.
Civitelli, S.
Tanzini, G.
Tani, F.
De Martino, A.
Marzocca, G.
Lorenzi, M.
Giorgi, G.
Francini, G.
Source :: British Journal of Cancer; 1/26/2004, Vol. 90 Issue 2, p306-309, 4p
Publication Year :: 2004
Abstract: A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2-73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand-foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC. [ABSTRACT FROM AUTHOR]

Full Text Access

Tools